Nanjing Leads Biolabs Co (FRA:0DX) PS Ratio: 58.13 (As of Aug. 26, 2026) — 15% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0DX Nanjing Leads Biolabs Co Ltd FRA:0DX
19 GF Score
Price €7.15
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co PS Ratio?

Nanjing Leads Biolabs Co FRA:0DX 19 PS Ratio is 58.13 as of Aug. 26, 2026, which is 15% below its 10-year median of 68.73. GuruFocus rates FRA:0DX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 931 Biotechnology companies, Nanjing Leads Biolabs Co ranks worse than 81.1% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nanjing Leads Biolabs Co's share price is €7.15. Nanjing Leads Biolabs Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.12. Hence, Nanjing Leads Biolabs Co's PS Ratio for today is 58.13.

The historical rank and industry rank for Nanjing Leads Biolabs Co's PS Ratio or its related term are showing as below:

FRA:0DX' s PS Ratio Range Over the Past 10 Years
Min: 44.11   Med: 68.73   Max: 1424.51
Current: 66.37

During the past 3 years, Nanjing Leads Biolabs Co's highest PS Ratio was 1424.51. The lowest was 44.11. And the median was 68.73.

FRA:0DX's PS Ratio is ranked worse than
81.1% of 931 companies
in the Biotechnology industry
Industry Median: 9.49 vs FRA:0DX: 66.37

Nanjing Leads Biolabs Co's Revenue per Sharefor the six months ended in Dec. 2025 was €0.12. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.12.

Back to Basics: PS Ratio


Nanjing Leads Biolabs Co  (FRA:0DX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Nanjing Leads Biolabs Co PS Ratio Related Terms


Nanjing Leads Biolabs Co PS Ratio Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co PS Ratio Chart

Nanjing Leads Biolabs Co Annual Data
Trend Dec23 Dec24 Dec25
PS Ratio
0.00 0.00 44.06

Nanjing Leads Biolabs Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
PS Ratio 0.00 0.00 0.00 0.00 44.06

FRA:0DX vs VRTX, REGN, RVMD: PS Ratio Comparison

For the Biotechnology subindustry, Nanjing Leads Biolabs Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Leads Biolabs Co PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where Nanjing Leads Biolabs Co's PS Ratio falls into.


FRA:0DX
19GF Score
Nanjing Leads Biolabs Co Ltd FRA:0DX
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Nanjing Leads Biolabs Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=7.15/0.123
=58.13

Nanjing Leads Biolabs Co's Share Price of today is €7.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanjing Leads Biolabs Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 58.13 mean?
Nanjing Leads Biolabs Co (FRA:0DX) has a PS Ratio of 58.13 as of Aug. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nanjing Leads Biolabs Co and its competitors. This is 15% below median its historical median of 68.73. Over the past decade, Nanjing Leads Biolabs Co's PS Ratio has ranged from 44.11 to 1,424.51. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #755 out of 931 companies in the Biotechnology industry, placing it in the top 81.1%.
Is Nanjing Leads Biolabs Co's PS Ratio too high?
Nanjing Leads Biolabs Co's current PS Ratio of 58.13 is 15% below median its 10-year median of 68.73. Over the past 10 years, this metric has ranged from a low of 44.11 to a high of 1,424.51. The Biotechnology industry median PS Ratio is 9.49. Nanjing Leads Biolabs Co's value of 58.13 is 512.5% above this industry median. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #755 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #755 out of 931 companies for PS Ratio. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median PS Ratio is 9.49. Nanjing Leads Biolabs Co's value of 58.13 is 512.5% above this benchmark. Historically, Nanjing Leads Biolabs Co's own PS Ratio has ranged from 44.11 to 1,424.51 over the past decade. While the company's 10-year median is 68.73 vs. the industry median of 9.49, Nanjing Leads Biolabs Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Leads Biolabs Co's current PS Ratio of 58.13 is 512.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nanjing Leads Biolabs Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current PS Ratio is 58.13, which is 15% below median its own 10-year median of 68.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current PS Ratio of 58.13. The current PS Ratio is 58.13, which is 15% below median its 10-year median of 68.73 and 512.5% above the Biotechnology industry median of 9.49. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current PS Ratio is 58.13 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 09887:Hong Kong
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score

Get the complete analysis for FRA:0DX

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.15
Price